import {virusInfoOrUndefinedF as virusInfoOrUndefinedF} from"/_js/functions.js"
import {availableVirusInfoF as availableVirusInfoF} from"/_js/functions.js"
import {availableToolsF as availableToolsF} from"/_js/functions.js"
import {virusOfInterestF as virusOfInterestF} from"/_js/functions.js"
// Initialize a container to contain the containers for the tree and annotation windowhtml`<!-- Show information on hovered virus, reuse the same class for convenience --><div class="phylo-container"> <!-- Left part --> <div class="left"> <div id="info-container" class="text-center" style="visibility:hidden;"> <div id="name" class="g-col-md-12 bold"> name </div> <div id="toolbox" class="g-col-md-12"> no tools yet for this virus </div> </div> </div> <!-- Right part --> <div id="annotation-container" class="right no-gutter"> <p> </p> </div></div><div class="phylo-container"> <!-- Left part --> <div class="left"> <div id="tree-container" class="tree-container"> <svg id="tree-svg" class="tree-svg"></svg> </div> <div id="legend-container" class="text-center mb-2"> <div class="grid"> <div class="g-col-md-12 small"> <span class="phylotree-node-text" style="font-size:15px !important;">HOVER</span> for more information / <span class="phylotree-node-text-hl" style="font-size:15px !important;">BOLD NODES</span> are present in collection and can be selected </div> </div> </div> </div> <!-- Right part --> <div id="annotation-container" class="right no-gutter"> <div class="container grid small" align="center" style="--bs-gap: 1.0rem;font-weight:500;"> <div class="g-col-md-12 g-col-sm-12 card card-body tool-header opacity-100" id="virus"> Viral Toolbox </div> </div> <div class="container"> <div class="toolbox"> <div id="toolbox-contents" class="tool-container"> </div> </div> </div> </div></div>`
name
no tools yet for this virus
HOVER for more information /
BOLD NODES are present in collection and can be selected
virusInfoOrUndefined =virusInfoOrUndefinedF(familyAnnotations)availableVirusInfo =availableVirusInfoF(familyAnnotations)availableTools =availableToolsF(familyAnnotations, toolbox)virusOfInterest =virusOfInterestF(familyAnnotations)// Initialize the toolbox when the data is loadedinit_toolbox = toolbox.map(tool => d3.select("#toolbox-contents").node().append(html` <a href=${get_link("toolbox","#"+ tool.id+"-section")} target="_top"> <div class="tool-wrapper"> <div id="${tool.id}" class="tool"> <div class="tool-tooltip-text">${tool.name}</div>${tool.icon.map( i =>html`<img class="tool-icon" height="${(tool.icon.length>1) ?150/tool.icon.length:100}%" src="${i}"/>` )} </div> </div> </a> ` ) )// Reset the tools in the ToolboxclearToolbox = () => { d3.select("#virus").text("Viral Toolbox") toolbox.map(tool => { d3.select("#"+ tool.id).attr("class","tool") })}// Update the tools in the toolbox based on the provided virus objectupdateToolbox = (virus) => { d3.select("#virus").text(virus.resVirusName) toolbox.filter(tool => virus.tools.includes(tool.id)).map(tool => d3.select("#"+ tool.id).attr("class","tool tool-selected") )}// Handle tabset depending on the number of tabsrawTabs = d3.select("#vb-tabset").select("ul").selectAll("li").select("a").nodes()nrTabs = rawTabs.lengthfunctionindexToTab(i, length) {const pre ="tabset-"+ (length +1) +"-"const post ="-tab"return pre + (i+1) + post}tabsetAnchor =indexToTab(0, nrTabs)virusIdToTabMap =newMap( toolboxAnnotatedViruses.map( (virus,i) => [ virus.resAbbreviation,indexToTab(i, nrTabs) ] ))tabToVirusIdMap =newMap(Array.from(virusIdToTabMap, a => a.reverse()))// Hide virus information tabsetfunctionhideTabset() {const virusInfo =document.getElementById(tabsetAnchor).parentNode.parentNode.parentNode virusInfo.style.display="none"}hide =hideTabset()// Instantiate treenwk = nwksAsMap[virusFamily]tree =new phylotree.phylotree(nwk) // class Phylotree// https://github.com/veg/phylotree.js/blob/master/src/main.js#L90// import { update_tree } from "/_js/functions.js"renderedTree = tree// Transform the tree (translate and prune)// based on the input Excel file for this virus family.traverse_and_compute(node => {const virus_id = node.data.nameconst isLeaf = tree.isLeafNode(node)if (isLeaf) {const virus =virusIdToVirus(virus_id)const isVirusOfInterest = (typeof virus !=="undefined") ? (virus.virus_of_interest=="Yes") :falseif (isVirusOfInterest) {const currentName = virus_idconst newName = virus.abbreviation.trim() node.data.name= newName } else { node.data.name="remove_me" tree.deleteANode(node) } } }).render({'width':600,'height':600,'left-right-spacing':'fit-to-size','top-bottom-spacing':'fit-to-size','is-radial':true,'selectable':false,'collapsible':false,'transitions':false,'show-menu':false,'show-scale':false,'align-tips':true,'zoom':false,'brush':false,'draw-size-bubbles':false,'maximum-per-node-spacing':500,'minimum-per-node-spacing':100,'maximum-per-level-spacing':500,'minimum-per-level-spacing':100,'container':"#tree-container" }).style_nodes( (element, data) => {// the virus_id is how the virus is encoded in phylotree newick fileconst virus_id = data.data.name// At this stage in the process, every node should have informationconst information =virusIdToVirus(virus_id) // virusInfoOrUndefined(virus_id)const inToolbox = (typeof information !=="undefined") && (information.availability_in_toolbox=="Yes")// Styling based on available informationconst updtElement1 = information ? element.select("text").attr("class","phylotree-node-text"): element.select("text").attr("class","phylotree-node-text-inactive")const updtElement = inToolbox ? element.select("text").attr("class","phylotree-node-text-hl") : element// Hover functionality - Virus nameif (information) element.on("mouseover",virusHoverIn(data, information, inToolbox)).on("mouseout", virusHoverOut)// Click functionality - Toolbox inToolbox? element.on('click',function(el) {clearToolbox();// Select the first tab in order to get to the root of the tabsetconst virusInfo =document.getElementById(tabsetAnchor).parentNode.parentNode.parentNode virusInfo.style.display="block" virusInfo.scrollIntoView(true)// Now get the proper tab and open itconst thisVirusInfo =document.getElementById(virusIdToTabMap.get(information.virusPointer)) // either the virus_id or the group abbreviation thisVirusInfo.click();// ExperimentsclearNodes()highlightNodes(virus_id)// Render the toolbox for this virusupdateToolbox(information); }): element.on('click',function() {hideTabset()clearToolbox() }) }).layout(true)// Based on a virus ID (abbreviation), highlight the virus or the whole group it belongs tohighlightNodes = (virus_id) => {const abbreviations =virusIdToViruses(virus_id).map(v => v.abbreviation) d3.selectAll("g").filter(function (d) { return (typeof d.data!=="undefined") ? abbreviations.includes(d.data.name) :false}).select("text").attr("class","phylotree-node-text-selected")}// Initialize all viruses in the treeclearNodes = () => {const inLst = annotatedViruses.map(v => v.abbreviation)const inToolboxLst = annotatedViruses.filter(v => v.availability_in_toolbox=="Yes").map(v => v.abbreviation)// Initialize all text d3.selectAll("g").filter(function (d) { return (typeof d.data!=="undefined") }).select("text").attr("class","phylotree-node-text")// Update toolbox entries d3.selectAll("g").filter(function (d) { return (typeof d.data!=="undefined") ? inToolboxLst.includes(d.data.name) :false}).select("text").attr("class","phylotree-node-text-hl")}// console.log(renderedTree)showTree = renderedTree.svg.node()// Show small virus information box on hovervirusHoverIn = (data, information, is_available) => () => {// First, populate the contentconst virusNameToShow = (information.resVirusName)? information.resVirusName: (typeof information.virus_name!=="undefined")? information.virus_name:"" d3.select("#name").text(virusNameToShow)if (information.tools.length>0) d3.select("#toolbox").text("Viral tools are available, please select the virus for more information")else d3.select("#toolbox").text("No viral tools have been developed yet")// ... then show the content d3.select("#info-container").attr("style","visibility:visible;")}virusHoverOut = () => { d3.select("#info-container").attr("style","visibility:hidden;")}// Clicking on the tabs feeds the info back to the toolbox infofeedbackToolbox = d3.selectAll(".nav-item").on('click',function(){const _id = d3.select(this).select("a").attr('id')const _virus_id = tabToVirusIdMap.get(_id)// We should only update the toolbox if an actual virus is selected// not if for instance the 'toolbox' tab is selectedif (typeof _virus_id !=="undefined") {const _virus =virusIdToVirus(_virus_id)clearToolbox();updateToolbox(_virus)clearNodes()highlightNodes(_virus_id) } })// Add SVG to the DOMtmp = d3.select("#tree-container").node().appendChild(showTree)// If the size of the SVG is smaller than the allocated 600px// then resize it relatively to the fraction// Allow for a bit of padding, hence the .95 factor.newSizeF = (curSize) => {if (curSize <600) {return600* (0.95*600/ curSize) } else {return curSize } }newSize =newSizeF(renderedTree.size[0])updateSize = renderedTree.set_size([newSize,newSize]).update()
nwk = "((((((((((((('L01442_VEEV IAB':0.025265000000000093,'AF375051_VEEV IC':0.012507000000000268):0.013702999999999577,'L00930_VEEV ID':0.025760000000000005):0.03417400000000015,AF075251_EVEV:0.08211299999999966):0.1542570000000003,'U34999_VEEV IE':0.20514200000000038):0.10617699999999974,AF075256_PIXV:0.3430460000000002):0.03991800000000012,(('AF075255_VEEV IIIC_71D1252':0.17995999999999945,'VEEV IIID_PE4-0800':0.15673199999999987):0.05496400000000001,(AF075254_TONV:0.12426300000000001,AF075253_MUCV:0.13084000000000007):0.05551399999999962):0.1353030000000004):0.04237800000000025,(AF075257_MDPV:0.24614399999999925,AF075258_RNV:0.22646099999999958):0.1724970000000008):0.10134699999999963,AF075259_CABV:0.2270310000000002):0.6514150000000001,((('DQ241303_MADV(EEEV Lin II':0.154706,'DQ241304_MADV(EEEV Lin III':0.11119400000000024):0.06964599999999965,'EF151503_MADV(EEEV Lin IV':0.16230299999999964):0.1118680000000003,EF151502_EEEV:0.14979600000000026):0.5686939999999998):0.24328199999999978,(((((((((NC_001547_SINV:0.03912199999999988,'M69205_SINV_Ockelbo virus':0.014482000000000106):0.0045000000000001705,'HM147984_SINV_Babanki virus':0.01222600000000007):0.06656700000000004,AF103728_SINV_XJ-160:0.19207899999999967):0.1310380000000002,AF429428_SINV_SW6562:0.2570300000000003):0.15468199999999932,HM147993_WHATV:0.32216999999999985):0.1095890000000006,((('GQ287646_WEEV(South America)':0.0877599999999994,'NC_003908_WEEV(North America)':0.06015399999999982):0.16328299999999984,GU167952_HJV:0.312449):0.19898300000000013,('HM147986_Buggy Creek virus (FMV)':0.030414999999999637,GQ281603_FMV:0.01359499999999958):0.44055400000000056):0.2050010000000002):0.29000000000000004,AF126284_AURAV:0.7464189999999995):0.2136130000000005,(NC_032681_TALV:0.4111799999999999,NC_018615_EILV:0.4835289999999999):1.7720590000000005):0.2152269999999996,HM147991_TROV:1.1633009999999997):0.2797640000000001):0.38134400000000035,U73745_BFV:1.1313240000000002):0.13628000000000018,((((((((AY702913_GETV:0.004532999999999454,'AB032553_GETV_Sagiyama virus':0.023095999999998895):0.28874400000000033,GQ433354_RRV:0.23964599999999958):0.19782300000000053,(HM147985_BEBV:0.6779240000000009,JF972635_SFV:0.3372660000000005):0.07050599999999996):0.05929099999999998,(HM147992_UNAV:0.43140100000000103,NC_003417_MAYV:0.6112350000000006):0.12869300000000017):0.13331799999999916,EF536323_MIDV:0.7100609999999996):0.1616900000000001,((AF079456_ONNV:0.014150000000000773,'AF079457_ONNV_Igbo Ora virus':0.006087000000000842):0.27097199999999955,KP003813_CHIKV:0.21552099999999985):0.8421139999999996):0.19801800000000025,HM147989_NDUV:1.1974039999999997):0.10722500000000057,HM147990_SESV:1.8602910000000001):0.06227799999999917):1.5085279999999992,AJ316246_SPDV:4.776731000000001);"
More than 50% of the infected patients develop a chronic, long-term disease, characterized by a debilitating arthralgia that can persist for weeks to months.
Death from MAYV is rare.
The virus is endemic to the tropical forests of the Amazon and was repeatedly detected in humans and mosquitoes in Latin America and the Caribbean. Despite being rarely fatal, MAYV infections have high socioeconomic impact due to the chronic painful incapacitating phase of the disease. There are no approved vaccines or antivirals available at the moment for the prevention or treatment of MAYV infection.
This antiviral assay measures the ability of a tested compound to protect infected cells from virus-induced cytopathic effects (mostly virus-induced cell death). The cell viability can be determined in a colorimetric assay using MTS/PMS method.
Virus yield assay
This antiviral assay measures the ability of a tested compound to inhibit the viral replication in an infected cell culture through quantifying the viral RNA and the infectious virus loads released in the supernatant. This assay can be used for validation of compounds that show efficacy in CPE-reduction assays and to confirm that the compounds have direct effect on viral replication (not only cytoprotective).
Delay of treatment assay (Time-of-addition)
This a test to determine the stage(s) of the viral replication cycle at which the compound exerts its antiviral effect. Briefly, cells are treated with the compound at different time points prior or after the infection with the virus then cells are incubated for example until the end of one or 2 replication cycles. At the end of incubation, the intracellular and extracellular viral RNA loads at each time point are quantified by qRT-PCR to determine at which stage(s) the compound is still effective and when it loses its antiviral efficacy.
Plaque assay
This assay is a standard method to quantify infectious virus titers in a sample. Briefly, the test sample is serially diluted then aliquot of each dilution is added to a well in a cell culture plate with incubation to allow virus attachment followed by removal of the viral input and adding overlay of agarose or similar viscous material that limit the spread of viral infection. Under this condition, the attached virion will start to replicate producing more virions that will kill surrounding cells to generate a hole or plaque in the cell monolayer. By removal of the overlay and staining the live cells for e.g. by Crystal violet or methylene blue, this will provide a dark background for clear visualization of plaques. By counting the plaques at certain dilution(s), the plaque forming units (PFU)/mL can be calculated.
Rodent models such as mice, rats and hamsters have been widely used to study viral infections. Such models allow to study host response and pathogenicity for wide variety of viruses. Moreover, these models are beneficial to assess the preclinical efficacy and safety of potential antivirals identified in cell culture assays.
Zebrafish models
Zebrafish (Danio rerio) are optically-transparent tropical freshwater fish of the family Cyprinidae that are widely used as vertebrate models of disease. They have remarkable genetic, physiologic and pharmacologic similarities to humans. Compared to rodents, the maintenance and husbandry costs are very low. Interestingly, zebrafish larvae have been shown to be susceptible to infection with some human viruses (herpes simplex virus type 1, influenza A virus, and chikungunya virus, human norovirus). Therefore, such a model can be used to study the pathogenesis as well as test antiviral drugs for specific human viruses in higher capacity and less cost compared to rodent models.
SFV is usually transmitted by female mosquitoes of the Aedes subspecies. Human cases are not common and can occur via spillover (Through bite of infected mosquitoes).
This antiviral assay measures the ability of a tested compound to protect infected cells from virus-induced cytopathic effects (mostly virus-induced cell death). The cell viability can be determined in a colorimetric assay using MTS/PMS method.
Virus yield assay
This antiviral assay measures the ability of a tested compound to inhibit the viral replication in an infected cell culture through quantifying the viral RNA and the infectious virus loads released in the supernatant. This assay can be used for validation of compounds that show efficacy in CPE-reduction assays and to confirm that the compounds have direct effect on viral replication (not only cytoprotective).
Delay of treatment assay (Time-of-addition)
This a test to determine the stage(s) of the viral replication cycle at which the compound exerts its antiviral effect. Briefly, cells are treated with the compound at different time points prior or after the infection with the virus then cells are incubated for example until the end of one or 2 replication cycles. At the end of incubation, the intracellular and extracellular viral RNA loads at each time point are quantified by qRT-PCR to determine at which stage(s) the compound is still effective and when it loses its antiviral efficacy.
Plaque assay
This assay is a standard method to quantify infectious virus titers in a sample. Briefly, the test sample is serially diluted then aliquot of each dilution is added to a well in a cell culture plate with incubation to allow virus attachment followed by removal of the viral input and adding overlay of agarose or similar viscous material that limit the spread of viral infection. Under this condition, the attached virion will start to replicate producing more virions that will kill surrounding cells to generate a hole or plaque in the cell monolayer. By removal of the overlay and staining the live cells for e.g. by Crystal violet or methylene blue, this will provide a dark background for clear visualization of plaques. By counting the plaques at certain dilution(s), the plaque forming units (PFU)/mL can be calculated.
A reverse genetic system is mostly a plasmid-based system that can be used to insert the desired mutations in the viral genome to study the effect of these mutations on viral replication, virulence, sensitivity to antiviral compounds in vitro and in vivo.
Reporter viruses
Reporter viruses are recombinant viruses engineered to carry reporter genes such as the one coding for fluorescent or luminescent proteins for development of high throughput antiviral assays or easily detection method for in vivo replication.
Several patients suffer from a chronic polyarthritis that can severely incapacitate the patient for weeks up to several years after the acute stage.
Death from chikungunya is rare.
Millions of CHIKV cases have been reported in the Caribbean region and several countries of Central and South America. Local transmission cases have been also reported in Europe (e.g. Italy and France). Despite being rarely fatal, CHIKV infections have high socioeconomic impact due to the chronic painful incapacitating phase of the disease. There are no approved vaccines or antivirals available for the prevention or treatment of CHIKV infection.
This antiviral assay measures the ability of a tested compound to protect infected cells from virus-induced cytopathic effects (mostly virus-induced cell death). The cell viability can be determined in a colorimetric assay using MTS/PMS method.
Virus yield assay
This antiviral assay measures the ability of a tested compound to inhibit the viral replication in an infected cell culture through quantifying the viral RNA and the infectious virus loads released in the supernatant. This assay can be used for validation of compounds that show efficacy in CPE-reduction assays and to confirm that the compounds have direct effect on viral replication (not only cytoprotective).
Delay of treatment assay (Time-of-addition)
This a test to determine the stage(s) of the viral replication cycle at which the compound exerts its antiviral effect. Briefly, cells are treated with the compound at different time points prior or after the infection with the virus then cells are incubated for example until the end of one or 2 replication cycles. At the end of incubation, the intracellular and extracellular viral RNA loads at each time point are quantified by qRT-PCR to determine at which stage(s) the compound is still effective and when it loses its antiviral efficacy.
Plaque assay
This assay is a standard method to quantify infectious virus titers in a sample. Briefly, the test sample is serially diluted then aliquot of each dilution is added to a well in a cell culture plate with incubation to allow virus attachment followed by removal of the viral input and adding overlay of agarose or similar viscous material that limit the spread of viral infection. Under this condition, the attached virion will start to replicate producing more virions that will kill surrounding cells to generate a hole or plaque in the cell monolayer. By removal of the overlay and staining the live cells for e.g. by Crystal violet or methylene blue, this will provide a dark background for clear visualization of plaques. By counting the plaques at certain dilution(s), the plaque forming units (PFU)/mL can be calculated.
HTS is an approach in antiviral drug discovery involving the use of automated equipment to rapidly test huge libraries of chemical or biological materials with the aim of identifying hit molecules against specific viruses. HTS is usually done in culture plates with 384 or 1536 wells format using high performance liquid/plate handling devices.
A reverse genetic system is mostly a plasmid-based system that can be used to insert the desired mutations in the viral genome to study the effect of these mutations on viral replication, virulence, sensitivity to antiviral compounds in vitro and in vivo.
Reporter viruses
Reporter viruses are recombinant viruses engineered to carry reporter genes such as the one coding for fluorescent or luminescent proteins for development of high throughput antiviral assays or easily detection method for in vivo replication.
Rodent models such as mice, rats and hamsters have been widely used to study viral infections. Such models allow to study host response and pathogenicity for wide variety of viruses. Moreover, these models are beneficial to assess the preclinical efficacy and safety of potential antivirals identified in cell culture assays.
Zebrafish models
Zebrafish (Danio rerio) are optically-transparent tropical freshwater fish of the family Cyprinidae that are widely used as vertebrate models of disease. They have remarkable genetic, physiologic and pharmacologic similarities to humans. Compared to rodents, the maintenance and husbandry costs are very low. Interestingly, zebrafish larvae have been shown to be susceptible to infection with some human viruses (herpes simplex virus type 1, influenza A virus, and chikungunya virus, human norovirus). Therefore, such a model can be used to study the pathogenesis as well as test antiviral drugs for specific human viruses in higher capacity and less cost compared to rodent models.
The virus is endemic to Central and South America where outbreaks in humans and equids have been reported in at least 12 countries. The mortality of VEEV in humans is lower than 1%, but neurological symptoms are seen in up to 14% of the infected persons. Currently, there is no approved antiviral or vaccine for treatment or prevention of VEEV infections in humans.
The toolbox for this virus is currently in development. Please contact us via info@virusbankplatform.be for more information.
Although many SINV infections are asymptomatic, SINV can result in a febrile illness associated with maculopapular rash and joint pain.
The virus is widely distributed throughout the world including Europe, Africa, Asia, and Australia. SINV is used as tool to study alphaviruses at lower biosafety level. There are no approved vaccines or antivirals available at the moment for the prevention or treatment of SINV infection.
This antiviral assay measures the ability of a tested compound to protect infected cells from virus-induced cytopathic effects (mostly virus-induced cell death). The cell viability can be determined in a colorimetric assay using MTS/PMS method.
Virus yield assay
This antiviral assay measures the ability of a tested compound to inhibit the viral replication in an infected cell culture through quantifying the viral RNA and the infectious virus loads released in the supernatant. This assay can be used for validation of compounds that show efficacy in CPE-reduction assays and to confirm that the compounds have direct effect on viral replication (not only cytoprotective).
Delay of treatment assay (Time-of-addition)
This a test to determine the stage(s) of the viral replication cycle at which the compound exerts its antiviral effect. Briefly, cells are treated with the compound at different time points prior or after the infection with the virus then cells are incubated for example until the end of one or 2 replication cycles. At the end of incubation, the intracellular and extracellular viral RNA loads at each time point are quantified by qRT-PCR to determine at which stage(s) the compound is still effective and when it loses its antiviral efficacy.
Plaque assay
This assay is a standard method to quantify infectious virus titers in a sample. Briefly, the test sample is serially diluted then aliquot of each dilution is added to a well in a cell culture plate with incubation to allow virus attachment followed by removal of the viral input and adding overlay of agarose or similar viscous material that limit the spread of viral infection. Under this condition, the attached virion will start to replicate producing more virions that will kill surrounding cells to generate a hole or plaque in the cell monolayer. By removal of the overlay and staining the live cells for e.g. by Crystal violet or methylene blue, this will provide a dark background for clear visualization of plaques. By counting the plaques at certain dilution(s), the plaque forming units (PFU)/mL can be calculated.
Some patients can suffer from a chronic long-term disease, characterized by a debilitating arthralgia that can persist for weeks to months.
Death from RRV is rare.
The virus is endemic in Australia, Papua New Guinea and other islands in the South Pacific. Despite being rarely fatal, RRV infections have high socioeconomic impact due to the chronic painful incapacitating phase of the disease. There are no approved vaccines or antivirals available for the prevention or treatment of RRV infection.
This antiviral assay measures the ability of a tested compound to protect infected cells from virus-induced cytopathic effects (mostly virus-induced cell death). The cell viability can be determined in a colorimetric assay using MTS/PMS method.
Virus yield assay
This antiviral assay measures the ability of a tested compound to inhibit the viral replication in an infected cell culture through quantifying the viral RNA and the infectious virus loads released in the supernatant. This assay can be used for validation of compounds that show efficacy in CPE-reduction assays and to confirm that the compounds have direct effect on viral replication (not only cytoprotective).
Delay of treatment assay (Time-of-addition)
This a test to determine the stage(s) of the viral replication cycle at which the compound exerts its antiviral effect. Briefly, cells are treated with the compound at different time points prior or after the infection with the virus then cells are incubated for example until the end of one or 2 replication cycles. At the end of incubation, the intracellular and extracellular viral RNA loads at each time point are quantified by qRT-PCR to determine at which stage(s) the compound is still effective and when it loses its antiviral efficacy.
Plaque assay
This assay is a standard method to quantify infectious virus titers in a sample. Briefly, the test sample is serially diluted then aliquot of each dilution is added to a well in a cell culture plate with incubation to allow virus attachment followed by removal of the viral input and adding overlay of agarose or similar viscous material that limit the spread of viral infection. Under this condition, the attached virion will start to replicate producing more virions that will kill surrounding cells to generate a hole or plaque in the cell monolayer. By removal of the overlay and staining the live cells for e.g. by Crystal violet or methylene blue, this will provide a dark background for clear visualization of plaques. By counting the plaques at certain dilution(s), the plaque forming units (PFU)/mL can be calculated.